Terns raises $87M to advance trials of NASH drugs
The startup, which licensed three NASH candidates from Eli Lilly, raised $87 million from the drugmaker and Deerfield Management.
Startup that lets doctors ask specialists for advice raises $18M
RubiconMD, a New York-based startup that gives primary care physicians access to advice from specialists, raised $18 million in funding. Private equity firm Deerfield Management Company led the startup’s most recent funding round.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Black Diamond, targeting untapped cancer mutations, files for $100M IPO
Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
Deerfield Management to spend $635M on New York life sciences hub
The healthcare investment management firm is working with the city's nonprofit economic development corporation and Chicago-based MATTER on the new project, which will focus on life sciences and digital health.
How do we get more women into boardroom and leadership roles?
As part of the second annual HLTH conference October 27-30 at the MGM Grand in Las Vegas will be a set of programming focused on how to get more women into the boardroom and leadership roles in healthcare and life sciences.
Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets
The company is targeting pathways such as SHP2 and KRAS G12C. RAS mutations have been an attractive target in oncology due to the central role they play in cancers.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Frontier Medicines launches with $67M Series A, hopes to go after ‘undruggable’ targets
Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.
Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies
The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
InCarda Therapeutics raises $42M in Series B for inhaled cardiovascular drug
The San Francisco-based company plans to use the money primarily to fund its ongoing Phase II study of the drug, which it initiated in May.
Epic Sciences raises $52M Series E round to advance liquid biopsy diagnostics
The San Diego-based firm plans to integrate its "No Cell Left Behind" platform with electronic medical records and big data analytics.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Allogene raises $120M for ‘off-the-shelf’ CAR-T development
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier's UCART19 and clinical development of its own allogeneic CAR-Ts next year.
Orchard Therapeutics closes $150 million Series C round
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
Medicare insider trading case casts a spotlight on political intelligence
Prosecutors allege that consultant David Blaszczak learned that Medicare was planning to cut the amount it reimburses doctors who used certain types of therapy on cancer patients and relayed the information to contacts at Deerfield Management.
Acutus Medical completes $75M Series C for its complex arrhythmia imaging system
The company's AcQMap technology provides a 3-D, high-resolution image of the heart’s interior and maps its electrical activity.
Hallux tackles toenail fungus with $7M from Deerfield
The company has developed a subungual micro-insert that treats toenail fungus at the site itself - avoiding systemic exposure to powerful antifungal drugs that are typically taken orally.